Oncternal Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Oncternal Therapeutics

30/10/2023 11:46

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results 
    * The San Diego California-based  company is expected to
report  a
67.3% decrease in revenue to $125 thousand from $382 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Oncternal
Therapeutics
Inc is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $2.25​, above​ its last closing price
of $0.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.14       -0.16      -0.15     Beat    6.3
 Mar. 31 2023  -0.20       -0.20      -0.20     Met     1.6
 Dec. 31 2022  -0.20       -0.21      -0.20     Beat    4​
 Sep. 30 2022  -0.24       -0.24      -0.21     Beat    11.3
 ​​Jun.        -0.22       -0.23      -0.23     Met     -0.7
 30 2022                                                
 Mar. 31 2022  -0.20       -0.20      -0.20     Met     1.2​
 Dec. 31 2021  -0.24       -0.25      -0.16     Beat    35
 Sep. 30 2021  -0.20       -0.16      -0.19     Missed  -18.7
 This summary was machine generated October 30 at 11:46 GMT.  All
figures in US dollars  unless otherwise stated